Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Kelly

Showing results (21-30 of 253) with videos related to

Pageof 26
Sort By:
Nature Clinical Practice. Urology|February 14, 2007
High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?Matthew D Galsky, William Kevin Kelly
Therapeutic Advances in Medical Oncology|June 15, 2010
Redefining hormone resistance in prostate cancerChristopher J Hoimes, W Kevin Kelly
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|July 6, 2023
Introduction of a Novel Ethics Curriculum to the Third-Year Psychiatry Clerkship ExperienceTim Kelly, Kevin Kelly, Paul Borghesani
Expert Review of Endocrinology & Metabolism|March 6, 2012
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerKaren E Knudsen, William Kevin Kelly
Update on Cancer Therapeutics|August 6, 2009
TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortalityChristopher J Hoimes, Wm Kevin Kelly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2013
Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancerJean Hoffman-Censits, Wm Kevin Kelly
Nature Clinical Practice. Oncology|November 3, 2005
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acidWilliam Kevin Kelly, Paul A Marks
Haematologica|March 3, 2009
Slow responses to standard dose rituximab in immune thrombocytopenic purpuraKevin Kelly, Mary Gleeson, Philip Thomas Murphy
Seminars in Oncology|June 29, 2013
Targeting epigenetics for the treatment of prostate cancer: recent progress and future directionsJianqing Lin, Chenguang Wang, Wm Kevin Kelly
Epilepsy & Behavior : E&B|December 24, 2013
Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?Martin J Brodie, Kevin Kelly, Linda J Stephen
Pageof 26

Showing results (21-30 of 253) with videos related to

Sort By:
Pageof 26
Nature Clinical Practice. Urology|February 14, 2007
High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?Matthew D Galsky, William Kevin Kelly
Therapeutic Advances in Medical Oncology|June 15, 2010
Redefining hormone resistance in prostate cancerChristopher J Hoimes, W Kevin Kelly
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|July 6, 2023
Introduction of a Novel Ethics Curriculum to the Third-Year Psychiatry Clerkship ExperienceTim Kelly, Kevin Kelly, Paul Borghesani
Expert Review of Endocrinology & Metabolism|March 6, 2012
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerKaren E Knudsen, William Kevin Kelly
Update on Cancer Therapeutics|August 6, 2009
TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortalityChristopher J Hoimes, Wm Kevin Kelly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2013
Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancerJean Hoffman-Censits, Wm Kevin Kelly
Nature Clinical Practice. Oncology|November 3, 2005
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acidWilliam Kevin Kelly, Paul A Marks
Haematologica|March 3, 2009
Slow responses to standard dose rituximab in immune thrombocytopenic purpuraKevin Kelly, Mary Gleeson, Philip Thomas Murphy
Seminars in Oncology|June 29, 2013
Targeting epigenetics for the treatment of prostate cancer: recent progress and future directionsJianqing Lin, Chenguang Wang, Wm Kevin Kelly
Epilepsy & Behavior : E&B|December 24, 2013
Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?Martin J Brodie, Kevin Kelly, Linda J Stephen
Pageof 26